
    
      A randomised, double-blind, placebo-controlled study to explore the antidepressant properties
      of the P38a kinase inhibitor GW856553X 15mg compared to placebo in subjects with Major
      Depressive Disorder exhibiting symptoms of loss of energy and interest, and psychomotor
      retardation, for a six week treatment period.
    
  